Abstract Both Parkinson's disease (PD) and stroke are debilitating conditions that result in neuronal death and loss of neurological functions. These two conditions predominantly affect aging populations with the deterioration of the quality of life for the patients themselves and a tremendous burden to families. While the neurodegeneration and symptomology of PD develop chronically over the years, post-stroke neuronal death and dysfunction develop rapidly in days. Despite the discrepancy in the pathophysiological time frame and severity, both conditions share common molecular mechanisms that include oxidative stress, mitochondrial dysfunction, inflammation, endoplasmic reticulum stress, and activation of various cell death pathways (apoptosis/necrosis/autophagy) that synergistically modulate the neuronal death. Emerging evidence indicates that several proteins associated with early-onset familial PD play critical roles in mediating the neuronal death. Importantly, mutations in the genes encoding Parkin, PTEN-induced putative kinase 1 and DJ-1 mediate autosomal recessive forms of PD, whereas mutations in the genes encoding leucine-rich repeat kinase 2 and a-synuclein are responsible for autosomal dominant PD. This review discusses the significance of these proteins with the emphasis on the role of a-synuclein in mediating post-ischemic brain damage.
Introduction
Chronic neurodegenerative conditions that include Parkinson's disease (PD), Alzheimer's disease (AD) and Huntington's disease (HD) show a progressive and irreversible loss of structure or function of neurons over time with devastating consequences that include a motor to cognitive dysfunction. 1 Although the pathophysiologic mechanisms responsible for neurodegeneration in chronic disorders are not completely understood, there are many commonalities including oxidative stress, mitochondrial dysfunction, endoplasmic reticulum (ER) stress, inflammation, autophagy, impairment of protein folding and abnormal post-translational modifications leading to overloading of the ubiquitinproteasome system. [2] [3] [4] [5] Furthermore, several proteins were shown to be associated with the progression of these disorders, particularly those that form aggregates in the CNS over time. 6, 7 For instance, one of the pathological hallmarks of PD is the presence of Lewy Bodies, proteinaceous cytoplasmic inclusions mainly composed of aggregated a-synuclein (a-Syn). 8 Similarly, AD is manifested by the accumulation of abnormally folded b-amyloid (Ab) and hyperphosphorylated tau in the brain, 9 and mutant and aggregated huntingtin proteins that disrupt retrograde transport in neurons play a pivotal role in the pathogenesis of HD. 10, 11 Neurodegeneration associated with acute conditions like stroke and traumatic brain injury (TBI) is also mediated synergistically by oxidative stress, mitochondrial dysfunction, apoptosis, inflammation, and autophagy which play critical roles in its pathogenic progression. [12] [13] [14] This similarity is surprising as the neuronal damage in chronic conditions like PD progresses over years, whereas acute conditions like stroke occur in a short span of hours to days. However, the intensity of mechanisms like oxidative stress, ER stress, and inflammation matches the time of progression as they are at a low, consistent level in chronic disorders, whereas they quickly go to a peak level and dissipate quickly in acute conditions. [15] [16] [17] Interestingly, it was shown that silent strokes could lead to PD via inflammatory responses. 18 In addition, there is a positive correlation of oligomeric form of PD-causing protein in the red blood cell between ischemic stroke and PD patients. 19 Furthermore, several proteins involved in the pathogenesis of PD have been reported to play proteopathic roles under the ischemic condition. In this review, we discuss the significance of these proteins with an emphasis on the role of a-Syn in promoting acute brain damage after stroke and the putative mechanisms of action.
Clinical implications of PD and cerebral ischemia
It has long been suggested that ischemic stroke is associated with PD. For instance, vascular Parkinsonism (VP), a form of atypical Parkinsonism, is produced by one or more small strokes, rather than by the gradual loss of nerve cells as seen in the more typical neurodegenerative PD. 20 Furthermore, levodopa treatment is known to be less effective and vascular risk factors were more common in VP patients compared to typical PD patients. 21 Supporting this phenomenon, a recent preclinical study revealed that silent striatal stroke induced by the middle cerebral artery occlusion in rodents, can cause PD and destroys dopaminergic neurons via inflammation in the substantia nigra. 18 Postmortem studies further raised the possibility of the coexistence of PD and cerebrovascular disease and suggest that patients with Parkinsonism may have cerebrovascular disease without the distinct pathological hallmarks of PD. 22, 23 Earlier clinical studies also reported a higher incidence of ischemic stroke in PD patients compared to control subjects. 24, 25 In particular, the proportion of deaths due to vascular lesions of the brain is significantly higher in male PD patients 45-64 years of age compared with the general population. 24 Despite such evidence, there is no direct evidence that PD-causing proteins are involved in the pathogenesis of clinical stroke cases. Although levels of oligomeric a-Syn in the red blood cells of ischemic stroke patients were found to be positively correlated with that of PD patients, 19 prospective studies are needed to clarify the role of PD proteins in human stroke cases.
The proteopathic basis of neurodegenerative processes in PD and ischemic stroke PD is the second most common neurodegenerative disease after AD characterized primarily by the loss of dopaminergic neurons in the substantia nigra pars compacta leading to a striatal dopamine deficit. Symptoms of PD include bradykinesia, hypokinesia, rigidity, resting tremor, postural instability, sleep disturbances, depression and cognitive impairment, indicating a more widespread degenerative process. 17 A pathological hallmark of sporadic PD is the presence of cytoplasmic proteinaceous inclusions called Lewy bodies, mainly composed of a-Syn, ubiquitin, neurofilaments, and molecular chaperones. 26 The role of Lewy bodies in the disease process and their status as a pathogenic marker of PD is still a matter of discussion. A breakthrough in PD research was the identification of genes which are responsible for monogenic familial forms. Although familial PD with specific genetic defects account for <10% of all cases of PD, the identification of these rare genes and their functions has provided tremendous insight into the pathogenesis of PD and opened up new areas of investigation. Mutations in the genes encoding Parkin, PINK1, and DJ-1 mediate autosomal recessive forms of PD and mutations in the genes encoding leucine-rich repeat kinase 2 (LRRK2) and a-Syn are responsible for autosomal dominant PD. Sporadic and monogenic forms share important clinical, pathological, and biochemical features, notably the progressive demise of dopaminergic neurons in the substantia nigra. Therefore, insight into the function and dysfunction of PD-associated gene products can help elucidate the underlying mechanisms and new pathways in cell death.
Cerebral ischemia triggers a series of complex biochemical and molecular events that promote neuronal death and neurological dysfunction. These include, but not limited to, excitotoxicity, ionic imbalance, edema, oxidative stress, ER stress, and inflammation.
14 These mechanisms promote necrosis as well as apoptosis and autophagy.
27 Surprisingly all these mechanisms are also known to be central in promoting brain damage in chronic conditions like PD although the intensity and timing are different between the acute and chronic diseases. Furthermore, recent studies showed that the chronic neurodegeneration-related proteins including a-Syn, DJ-1, Parkin and PINK1 are also involved in the neuronal death following acute insults like a stroke.
-Synuclein
The structure of -Syn. a-Syn is a small protein (14.5 kDa; 140 amino acid) abundantly expressed in the mammalian brain and localized primarily in presynaptic terminals. a-Syn has three structural domains: the amphipathic N-terminal region (residues 1 to 60), the central hydrophobic region (residues 61 to 95; also known as NAC; non-amyloid component) and the acidic C-terminal region (residues 96 to 140) (Figure 1 ). The N-terminal region is well conserved and binds to phospholipids to acquire an amphipathic a-helix structure. 28 The central hydrophobic region enables aSyn to form aggregates, rich in b-pleated sheets upon aggregation. The tertiary interactions between the three domains are known to stabilize and shield the NAC region from undergoing spontaneous oligomerization of a-Syn. 29, 30 At least five missense mutations in the N-terminal and several post-translational modifications including nitroxidation, phosphorylation, and ubiquitination in both the N-and C-terminals are implicated in the pathogenesis of PD and other synucleinopathies as they disrupt the intrinsic autoinhibitory mechanisms leading to oligomerization of a-Syn.
31-35
Oligomeric -Syn and the cellular toxicity. a-Syn aggregates, the major component of Lewy bodies, are implicated in the cytotoxicity and the pathogenesis of several neurodegenerative disorders. [36] [37] [38] However, soluble oligomeric intermediates are considered as the major precipitators of PD pathology as mature fibrils are deemed benign precipitates by sequestration of toxic oligomers. [39] [40] [41] Biochemical and genetic studies suggest that a-Syn directly interacts with a number of key players in the pathogenesis of synucleinopathies (Figure 2 ). a-Syn oligomers are thought to form annular structures and pore-like complexes in the lipid bilayer of the membranes resulting in disruption of calcium homeostasis. [41] [42] [43] [44] [45] However, a-Syn oligomers were also thought to induce membrane permeabilization independent of pore-like complexes. 46 ,47 a-Syn can also promote mitochondria-independent reactive oxygen species (ROS) production, by interacting with metal ions. In vitro studies showed that a-Syn has several binding sites for copper and the redox activities of a-Syn-Cu þ complexes can generate hydrogen peroxide, 48, 49 and these a-Syn-copper complexes are found to be neurotoxic and promote further oligomerization. 50, 51 The unfolded protein response (UPR) and the subsequent ER stress are neuroprotective in moderation. However, prolonged and/or excessive ER stress leads to neuronal death. 52 In the brain of PD patients, expression of UPR activation markers, phospho-PERK and phospho-eIF2a, was observed to be increased and Figure 1 . The primary structure of a-Syn. a-Syn monomeric protein consists of an amphipathic N-terminal (amino acids 1-60; Red), a hydrophobic non-amyloid component (NAC; amino acids 61-95; Blue) and an acidic C-terminal (amino acids 96-140; Green). The N-terminal region is highly conserved between the synuclein family proteins and contains characteristic consensus apolipoprotein lipid-binding motifs (KTKEGV). This region adopts an amphipathic a-helical structure upon binding to negatively charged lipids, such as phospholipids present on cellular membranes. The central region is a hydrophobic zone that corresponds to the non-amyloid component and holds the amyloidogenic properties of the protein which allows a-Syn to undergo fibrillization, rich in b-structures. The C-terminal region is a negatively charged acidic segment rich in glutamic, aspartic, and proline residues which hosts several posttranslational modification sites including S129. Five missense mutations identified to date (purple) as well as the S129 phosphorylation site (blue) are marked with arrowheads. KTKEGV repeat motifs within the N-terminal are shown in bold. Amino acids associated with nitroxidative modifications (methionine, tyrosine, and histidine) present in either the N-terminal or the C-terminal region are underscored.
colocalized with a-Syn. 53 An in vivo study further showed that toxic a-Syn oligomers accumulate within ER lumen and a-Syn oligomer-dependent ER stress can be rescued by treatment with Salubrinal, which inhibits eIF2a and thus decreases protein overload 54, 55 . a-Syn oligomers are also shown to be promote inflammatory responses 56, 57 and autophagy.
58,59
-Syn and mitochondrial dysfunction. Mitochondrial homeostasis are dependent on fusion and fission dynamics, and their perturbation results in mitochondrial dysfunction which is implicated in neurodegenerative disorders. 60 In the brains of PD patients, aggregated a-Syn was observed to be localized in the inner mitochondrial membranes where it interacts with complex I resulting in the reduced mitochondrial complex I activity and increased ROS production. [61] [62] [63] a-Syn aggregates also interact with other mitochondrial proteins such as carbonic anhydrase, enolase, and lactate dehydrogenase which were found to be oxidized in brains of transgenic mice overexpressing mutant A30P a-Syn.
64 a-Syn overexpression was shown to significantly increase the translocation of mitochondrial fission protein Drp1 via extracellular signal-regulated kinase (ERK) pathway 65 and induced mitochondrial cytochrome C release and caspase-9 and -3 activities promoting apoptosis. 55, 66 In contrast, inhibition of a-Syn expression prevented MPP þ -induced mitochondrial fragmentation in vitro. 67 As mitochondrial dysfunction is thought to be a key player in Figure 2 . Mechanism of oligomeric a-Syn-mediated cellular toxicity in PD. In a normal physiological condition, a-Syn has long been known to exist as an unfolded monomer. However, recent evidence suggests that a-Syn under normal physiological state may exist as tetramers that resist aggregation. Tetrameric a-Syn species become destabilized and prone to aggregation due to several pathologic factors including point mutations, ROS generated by dysfunctional mitochondria and post-translational modifications like phosphorylation and nitroxidation. Concomitantly, impaired ubiquitin-proteasomal system (UPS) may not effectively clear the misfolded proteins resulting in the accumulation of oligomeric a-Syn species. a-Syn aggregates, in turn, increase cellular toxicity by several mechanisms. The a-Syn oligomers (1) permeabilize the lipid bilayer by forming Ca 2þ -permeable pore-like complexes thereby disturbing intracellular calcium homeostasis, (2) promote mitochondrial fragmentation by directly interacting with mitochondrial complex I, recruiting mitochondrial fission protein Drp1 and inhibiting DJ-1/PINK1/Parkin proteins that are known to maintain mitochondrial integrity, (3) activate the prolonged unfolded protein response (UPR) by accumulating within the ER lumen, and (4) generate mitochondria-independent ROS via redox activities with metal ions.
neurodegeneration, these studies suggest that a-Syn could potentially play a pathogenic role in a broad spectrum of neurodegerative diseases.
-Syn and post-translational modifications. As discussed above, post-translational modifications are known to impact the pathological role of a-Syn including its aggregation, fibrillation, Lewy body formation and neurotoxicity. Of various post-translational modifications a-Syn can undergo, serine-129 (S129) phosphorylation is considered as a defining hallmark of PD and other synucleinopathies. 68, 69 In the post-mortem PD patient brains, > 90% of the a-Syn aggregates are known to be S129 phosphorylated, but its functional significance is not yet completely elucidated. 70 Many kinases can promote S129 phosphorylation of a-Syn, and overexpression of GRK2 and GRK6 in Drosophila 71 and rodent PD models 72 showed enhanced and accelerated neuronal death. In contrast, overexpression of Polo-like kinase 2 (PLK2) which also mediates a-Syn S129 phosphorylation was shown to reduce a-Syn-associated dopaminergic neuronal loss and ameliorate hemiparkinsonian motor impairment presumably by enhancing autophagy in adult rodents. 73 Although further studies are required for elucidating the exact function of S129 phosphorylation on a-Syn toxicity, these studies emphasize the significance of the kinase responsible for the phosphorylation rather than the phosphorylation itself.
-Syn: Unanswered questions. Although extensive research over the last two decades has provided tremendous insight into the role of a-Syn in the pathogenesis of PD, there are still many unanswered questions that need to be addressed for developing therapies targeting a-Syn. While the predominant view is that a-Syn exists as an unfolded monomer under native conditions, recent studies showed that a-Syn may exist as a helically folded tetramer that resists aggregation and fibrillation in the normal brain. 74, 75 Neurons derived from PD patients expressing A53T mutant a-Syn contained decreased tetramers. 76 In vitro studies further showed that a-Syn missense mutations (A30P, E46K, and A53T) lower a-Syn tetramer: monomer ratio and induce neurotoxicity and round inclusions. 76 In addition, mutagenesis studies revealed that the a-Syn KTKEGV repeat motifs present in the N-terminus mediate physiological tetramerization and perturbing them causes PD-like neurotoxicity. 77 Despite these studies, it is not convincingly established if a-Syn exists as a monomer or a tetramer under normal conditions. 78, 79 Another enigma regarding a-Syn pathology is the mechanisms that modulate a-Syn expression during pathological states. Interestingly, microRNAs miRNA-7 and miRNA-153 were shown to synergistically target a-Syn mRNA to repress its protein expression. 80, 81 In human embryonic kidney cells (HEK293T) challenged with hydrogen peroxide, premiR-7 transfection decreased a-Syn protein expression and cell death. 81 In addition to direct effects of miRNAs on the a-Syn protein expression, these small non-coding RNAs may also have indirect implications for the a-Syn pathology in a specific cell type. For example, miR-155 knockout mice showed reduced microgliosis and neuroprotection despite a-Syn overexpression. 82 miR-155 was also observed to be essential for a-Syn-induced major histocompatibility complex class II (MHCII) and inducible nitric oxide synthase (iNOS) expression in microglia. 82 Although further studies are needed, these findings not only provide mechanisms by which a-Syn levels are regulated in disease brains but also raise the possibility that miRNA based therapy is feasible for a-Synucleinopathies.
-synuclein and stroke. Interestingly, cellular environment following cerebral ischemia that includes inflammation, oxidative stress and ER stress potentially provides optimal conditions for a-Syn aggregation. In PD and other chronic neurodegenerative conditions, a-Syn aggregates exacerbate cellular toxicity by interacting with lipid membranes, 41 metal ions, 48 ER, 54 and mitochondria. 63 Stroke can also either initiate or accelerate progressive neurodegenerative processes and is a known epidemiologic risk factor for AD. 83 Significance of a-Syn in modulating ischemic brain injury was demonstrated by multiple labs (Table 1) . Ishimaru et al. 84 and Polymeropoulos et al. 85 showed that a brief global ischemia in gerbils resulted in increased a-Syn (aka precursor protein of non-Ab component of AD amyloid; NACP) immunoreactivity in the hippocampus where neurons died and proposed that NACP may be related to several neurodegenerative conditions. Subsequently, Hu et al. 86 showed that hypoxia/ischemia increases a-Syn protein levels in the rat cerebral cortex, and Yoon et al. 87 reported increased a-Syn immunoreactivity and protein levels in the hippocampal CA1 region following global ischemia in gerbils and this process was more prominent in aged than young animals. 87 More importantly, increased a-Syn expression and neuronal death were attenuated by treatment with the antioxidant enzyme SOD1, indicating that ROS promotes a-syn expression and aggregation. 87 Furthermore, global cerebral ischemia in a-Syn knockout mice resulted in increased prostaglandin levels indicating the role of a-Syn in mediating post-ischemic inflammatory responses. 88 This study suggested that a-Syn induction after ischemia may be neuroprotective by reducing the post-ischemic brain prostaglandin formation, but later studies challenged this notion. Although prostaglandin is implicated in both pro-inflammatory and anti-inflammatory responses in different biologic systems, 89 a recent in vivo study showed that stimulation of prostaglandin D2 receptor DP1 is neuroprotective in the rodent ischemic brain. 90 Furthermore, Unal-Cevik et al. 91 reported that a brief ischemic insult is sufficient to induce a-Syn aggregation in neurons in adult mice. When subjected to a brief ischemia, a-Syn overexpressing transgenic mice showed exacerbated infarction and enhanced 3-nitrotyrosine immunoreactivity, indicating oxidative/ nitrative stress as a potential mechanism of a-Synmediated toxicity similar to what was shown in PD. Recent studies from our laboratory also conclusively demonstrated that a-Syn induced after transient focal ischemia plays a detrimental role. 92 We observed that transient focal ischemia induced by MCAO in adult rats significantly upregulates a-Syn mRNA and protein levels, and knockdown of a-Syn decreases infarction and promotes better neurobehavioral recovery. Knockdown of a-Syn also attenuated known ischemic pathological markers including mitochondrial dysfunction (Drp1), apoptosis (cleaved caspase-3), autophagy (LC-3 II/I ratio) as well as oxidative stress (3-nitrotyrosine). In addition, we observed that a-Syn protein oligomerizes, aggregates, and translocates to neuronal nuclei in both rat and human post-stroke brain. a-Syn knockout mice showed curtailed mortality, smaller infarcts, and better neurological recovery when subjected to transient focal ischemia. Furthermore, we observed that phosphorylation of a-Syn is responsible in part for its toxicity in the post-stroke brain as mice that lack PLK2 (the predominant kinase that mediates S129 phosphorylation of a-Syn) showed better functional recovery and smaller infarct after transient focal ischemia. 92 These studies show that a-Syn plays a critical role even in the pathogenesis of ischemic stroke. Prospective studies will elucidate the exact mechanisms of a-Syn-mediated ischemic cell death.
Parkin
Parkin is a widely expressed cytosolic ubiquitin E3 ligase in the brain that mediates mono-and polyubiquitination of many proteins to regulate a variety of cellular processes. A number of proteins identified as Parkin substrates are implicated in the pathogenesis of PD. Among those, Parkin-mediated degradation of the GTPase cell division control-related protein-1 (CDCrel-1), is known to induce dopaminergic neurodegeneration in the rodent brain. 93, 94 In addition, overexpression of Parkin-associated endothelin receptor-like receptor (Pael-R) induces the unfolded stress response in dopaminergic neurons, and Parkin attenuates insoluble Pael-R-mediated cellular toxicity presumably through ubiquitination. 95 Furthermore, the a-Syn-interacting protein, synphilin-1, interacts with and is polyubiquitinated by Parkin leading to the formation of protein aggregates when overexpressed together with a-Syn. 96 Recent studies suggest that lysine-63-mediated ubiquitination on synphilin-1 may participate in the degradation of Lewy body inclusion independent of the UPS, implicating its role in the inclusion formation. 97 Overall, the catalytic activities of Parkin were shown to be neuroprotective and counters diverse cellular insults including a-Syn toxicity and UPS dysfunction, 98 accumulation of Pael-R (a substrate of Parkin), 95 and kainite-induced excitotoxicity. 99 Parkin gene is a common cause of monogenic PD, and Parkin can undergo > 100 types of mutations including exonic rearrangements, point mutations, and small deletions or insertions. 100 Furthermore, Parkin can be inactivated by post-translational modifications due to oxidative and nitrosative stress as seen in sporadic PD. 101, 102 Parkin inactivation leads to accumulation of Parkin substrates like aminoacyltRNA synthetase-interacting multifunctional protein type 2 (AIMP2) and far upstream element-binding protein 1 (FBP1) which leads to neurodegeneration in PD. 103, 104 The nonreceptor tyrosine kinase c-Abl phosphorylates tyr-143 and thus inhibits ubiquitin E3 ligase activity of Parkin leading to neuronal degeneration in rodent MPTP model. 105 Concomitantly, activated cAbl further contributes to a-Syn-induced neurodegeneration in the rodent brain. 106 Parkin inactivation also leads to induction of its substrates PARIS (ZNF746) and RTP801/REDD1, which promote dopaminergic neurodegeneration. Once accumulated, PARIS represses the peroxisome proliferator-activated receptor gamma-coactivator 1-alpha (PGC-1a) and its downstream neuroprotective target gene NRF-1, 107 while RTP801/REDD1 is a negative regulator of survival kinases mTOR and Akt and hence promotes apoptosis. 108 Taken together, these studies indicate that Parkin is an essential neuroprotective protein, and its inactivation promotes neurodegeneration.
PINK1
PTEN-induced kinase 1 (PINK1) is a mitochondrial serine-threonine kinase that is ubiquitously expressed throughout the brain and is found in most cell types. 109 More than 40 mutations in PINK1 gene are known to promote autosomal recessive PD. 110, 111 Several lines of evidence indicate that PINK1 is also a neuroprotective protein. An early study showed that wild-type, but not mutant PINK1 protects SH-SY5Y cells against stressinduced mitochondrial dysfunction and apoptotic cell death. 42 Depletion of PINK1 both in vitro and in vivo was shown to exacerbate a-Syn aggregation-mediated toxicity as well as promote proteasomal inhibition. 112, 113 In contrast, reinstating PINK1 in Drosophila can rescue a-Syn-induced pathologic phenotypes although the mechanisms of how PINK1 mitigating a-Syn toxicity are not clearly known.
114 PINK1 colocalizes and phosphorylates TRAP1 (TNF receptor-associated protein 1; HSP75), which is a protein chaperone that protects mitochondria from oxidative stress. 115 In Drosophila, TRAP1 overexpression was shown to rescue PINK1 loss-of-function phenotypes. 116 Much attention is given to the role of PINK1 in conjunction with Parkin in promoting the clearance of impaired mitochondria. Termed mitophagy, it is the highly selective autophagy-based process representing a critical mechanism to eliminate damaged and dysfunctional mitochondria, thus protecting cells from aging, oxidative stress, and even apoptotic cell death. 117 When mitochondria are damaged, mitochondrial membrane depolarization leads to PINK1 accumulation on the outer membrane, which recruits Parkin from cytosol that ubiquitinates mitofusin 1, mitofusin 2 and P62/SQSTM1 that promotes mitophagy to recycle the healthy mitochondrial components. [117] [118] [119] [120] [121] [122] [123] [124] A recent study suggested that PINK1 can also promote mitophagy without involving Parkin by directly phosphorylating autophagy receptors NDP52 and optineurin which in turn recruit the autophagy factors ULK1, DFCP1, WIPI1 as well as LC3. 125 This evidence indicates that PINK1 and Parkin, the two genes implicated in the autosomal recessive PD, work together in the same pathway to govern mitochondrial quality control, bolstering previous evidence that mitochondrial damage is involved in PD.
Similar to their role in PD and other neurodegenerative disorders, even after stroke, Parkin and PINK1 are thought to regulate the mitochondrial integrity and thereby protect neurons from stress-induced mitochondrial dysfunction. [126] [127] [128] Transient focal ischemia in adult mice was shown to markedly downregulate Parkin protein expression within the first 24 h of reperfusion. 129 Overexpression of Parkin in primary cortical neurons further showed that neurons were protected from injury induced by ER stress which is a known mediator of post-ischemic secondary brain damage. 129 On the contrary, treatment of mice subjected to transient focal ischemia with ER stress inducers tunicamycin and thapsigargin prevented post-ischemic Parkin depletion leading to its translocation to mitochondria and activation of mitophagy. 130, 131 In addition, the neuroprotective effects of these ER stress inducers were reversed by Parkin knockdown and/or knockout. 130, 131 Surprisingly, recent studies showed that Parkin and PINK1 were upregulated in cortical penumbra following photothrombotic focal ischemia in rats and promote the survival of penumbral neurons. 132 133 Moreover, Parkin protein upregulation was also shown in the rat brain after transient focal cerebral ischemia induced by MCAO. 134 Thus, it is still premature to conclude the definitive role of Parkin in ischemic brain damage.
DJ-1
DJ-1 is a small ubiquitously expressed protein in the brain that exists as a homodimer in cytoplasm, mitochondria, and nucleus.
135-137 DJ-1 is an oxidative stress response protein that defends cells against ROS. [138] [139] [140] DJ-1 is thought to help maintain the integrity of mitochondria, presumably by interacting with complex I, and thereby minimizing the production of mitochondria-dependent oxidative stress leading to cytoprotection. 141 Loss of DJ-1 leads to pathological mitochondrial phenotypes including reduced membrane potential, 142 increased fragmentation, 143, 144 and accumulation of autophagic markers. 145 Studies showed that brains of AD and PD patients contain high levels of oxidized DJ-1 which is thought to be neuroprotective. 146, 147 The neuroprotective potential of DJ-1 is considered to be due to post-translational modifications including oxidation of cysteine C106, [148] [149] [150] [151] [152] SUMOylation of lysine K130 153, 154 and transnitrosylation of cysteine residues C46, C53, and C106. 155 Especially, from the transnitrosylated C106 residue, the NO group can be transferred to phosphatase and tensin homolog (PTEN) that decreases its phosphatase activity leading to neuronal survival.
156
Although DJ-1 directly quenches some ROS via oxidation of Cysteine residues, this effect is not deemed a major contributor to the protective function of DJ-1. 157 The neuroprotective activity of DJ-1 is thought to be multifactorial that includes chaperoning misfolded proteins including a-Syn and controlling its aggregation, [158] [159] [160] activating SOD1 161 and modulating transcriptional regulators like p53, 162, 163 nuclear factor erythroid 2-related factor 2 (Nrf2) 164, 165 and proteinassociated splicing factor (PSF) 166 as well as by acting as a cysteine protease.
167,168 DJ-1 acts in parallel with PINK1/Parkin to protect mitochondria during oxidative stress. Overexpression of Parkin or PINK1 prevents rotenone-induced mitochondrial fragmentation in the absence of DJ-1 in human dopaminergic cells. 145 On the contrary, DJ-1 overexpression ameliorates PINK1, but not Parkin mutant-mediated mitochondrial dysfunction in Drosophila. 169 Furthermore, mitochondrial fragmentation induced by a-syn overexpression in C. Elegans was shown to be mitigated by coexpression of wild-type PINK1, Parkin or DJ-1 with a-Syn but not by mutant forms of PINK1, Parkin or DJ-1. 170 DJ-1 is the most studied PD-causing protein in ischemic stroke setting due to its known neuroprotective roles in PD and other neurodegenerative conditions as an antioxidant as well as redox-sensitive molecular chaperone. Consistent with previous findings in PD, several studies showed that focal ischemia in rodents induces DJ-1 protein expression which prevents ischemic neuronal death by suppressing ROS production and acting as a redox-sensitive molecular chaperone. 134, [171] [172] [173] [174] Biochemical and immunocytochemical studies revealed that when rat primary neuronal cultures were subjected to oxygen-glucose deprivation, DJ-1 translocates to mitochondria and nucleus which was thought to protect the cells. 175, 176 Interestingly, the translocated mitochondrial DJ-1 was subsequently observed to be secreted into the medium which is an essential step in DJ-1-mediated neuroprotection. 175, 176 In vivo and in vitro studies also showed the significance of astrocytic DJ-1 in response to post-ischemic oxidative stress. 177 Following focal ischemia, activated astrocytes induced DJ-1 expression in the rat brain. Furthermore, when primary astrocytic cells were treated with H 2 O 2 , DJ-1 was observed to be secreted from astrocytes and scavenged hydroxyl radicals. However, the functional significance DJ-1 secretion is not clear yet.
Judging from previous evidence from PD and other neurodegeneration models, a-Syn aggregates might prevent the neuroprotective potential of DJ-1 after ischemia (Figure 3 ). Brain tissue from PD patients was shown to contain large molecular complexes (>2000 kDa) of a-Syn and DJ-1. 178, 179 In addition, decreased DJ-1 solubility was observed in the brains of PD patients. 178, 180 These studies suggest that a-Syn aggregates recruit DJ-1 to form insoluble inclusions and thereby attenuate its antioxidant neuroprotective ability. DJ-1 may also exert cellular protection by regulating transcription factors involved in the cell death. In support to this notion, DJ-1 was shown to negatively regulate p53 in response to oxidative stress. 154, 162 In zebrafish model of PD, DJ-1 deficiency resulted in increased p53 and Bax (apoptosis regulator) expression when challenged by H 2 O 2 .
181 Activation of p53 is also involved in apoptotic cell death in cerebral ischemia and in vivo administration of p53 inhibitor pifithrin-a induced neuroprotection in rats subjected to focal ischemia. [182] [183] [184] Taken together, it could be hypothesized that ischemic stress-induced a-Syn accumulation contributes, at least in part, to the increased p53 levels via suppressing DJ-1 solubility.
LRRK2
Leucine-rich repeat kinase 2 (LRRK2) is a multidomain protein (280 kDa, 2527 amino acid) which contains a central catalytic core that includes a Ras of complex (ROC), a GTPase protein domain, a carboxy-terminal of Roc (COR) domain and a kinase domain. The central catalytic core is surrounded by several potential protein-protein interacting domains including leucine-rich repeats and the WD40 domain. 185 Mutations in the LRRK2 (R1441C, R1441G, and R1441H in the ROC domain, G2019S and I2020T in the kinase domain and Y1699C in the COR domain) are thought to be responsible for both familial and sporadic PD. 186 Although the exact functional consequences of various LRRK2 mutations are not known, mutations in the ROC and COR domains decrease GTPase activity while mutations in the kinase domain increases kinase activity. [187] [188] [189] Among the known LRRK2 mutations, G2019S mutation in the kinase domain shows the most prevalence in PD population. 190, 191 As G2019S mutation is the most prevalent in the PD population, increased LRRK2 kinase activity by G2019S mutation implicates significance in the pathogenesis of monogenic PD. In addition, polymorphism within the LRRK2 gene is also correlated with sporadic PD risk. 192, 193 Many studies further showed that LRRK2 variants that include A419V, R1628P, and G2385R mutations increase risk for sporadic PD in Asians. [194] [195] [196] Interestingly, there might be an association between LRRK2 and other PD genes; and many PD patients with LRRK2 mutations exhibit a-Syn-positive Lewy bodies and tau-related pathology. 197, 198 LRRK2 is known to phosphorylate Tau directly or indirectly by activating GSK-3b which is a predominant Tau kinase. [199] [200] [201] Tau is a microtubule-associated protein that is predominantly expressed in CNS and regulates neurite outgrowth and axonal transport by modulating tubulin assembly and microtubule stability. 202 Hence, proper functioning of Tau is essential for neuronal plasticity and memory consolidation. The microtubule-binding ability of Tau is regulated by several post-translational modifications.
Particularly, hyperphosphorylation of Tau promotes neuronal degeneration, and the fibrillar deposits of highly phosphorylated Tau is a defining marker of neurodegeneration including. 203 Studies in PD and AD models showed co-localization of a-Syn with phospho-GSK-3b and phospho-Tau, and indicated that aSyn may act as a scaffolding molecule that is necessary for the activation of GSK-3b and the subsequent Tau hyperphosphorylation. 204, 205 Taken together, these studies indicate that LRRK2 may be critically involved in the Tau pathology in PD.
As indicated above, LRRK2 activates GSK-3b by phosphorylation leading to tau hyperphosphorylation in PD. 204, 205 In parallel to this, cerebral ischemia in rodents was shown to increase GSK-3b-mediated tau hyperphosphorylation that colocalizes with TUNEL staining implicating its role in apoptotic cell death. 206, 207 Concomitantly, GSK-3b downregulates Nrf2 following cerebral ischemia, 208 which is known -permeable NMDA receptors and subsequent Ca 2þ influx activates intracellular Ca 2þ sensitive enzymes such as nNOS. Oxidative stress produced by ROS damages organelles including mitochondria and promotes aggregation of aSyn. Following ischemic insult, DJ-1 translocates into neuronal mitochondria and nuclei to act as an antioxidant and molecular chaperone. Once translocated, DJ-1 negatively regulates proapoptotic factors like p53 and Bax and inhibits apoptotic cell death. DJ-1 is also secreted into the extracellular space, but its functional significance is not yet clear. Upon ischemic stress, aggregated a-Syn may form higher molecular weight complexes with DJ-1 resulting in decreased solubility and bioavailability of DJ-1.
to reduce levels of hyperphosphorylated tau protein by inducing autophagy adaptor protein NDP52. 209 Furthermore, a-Syn was shown to be induced following cerebral ischemia and its knockdown decreases postischemic mitochondrial fragmentation and apoptosis. 92 Thus, LRRK2 might contribute to post-ischemic apoptotic cell death as well by modulating tau phosphorylation in the presence of a-Syn (Figure 4) . Future studies will show the functional significance of LRRK2 to post-stroke brain damage.
Conclusions
The pathophysiologic mechanisms of neuronal death and therapeutic development for chronic neurodegenerative diseases like PD and acute injuries like stroke are usually investigated separately. However, many molecular mechanisms that promote secondary brain injury like inflammation, oxidative stress, ER stress, apoptosis, and autophagy can be seen in both chronic and acute CNS insults although their intensity and timing are different. Furthermore, observations like aggregation of a-Syn and depletion of proteins like DJ-1, PINK1, and Parkin after cerebral ischemia suggest that the mechanisms that are known to promote pathology in chronic conditions might also contribute to neuronal death after stroke. However, the causal relationship between the chronic neurodegenerationassociated proteins and cell death in stroke remains to be established beyond doubt. It is possible that neuronal cell injury may be caused by a direct toxic effect of protein aggregates or protein depletion. Conversely, abnormal protein levels could arise due to the pathological cellular environment created by injured neurons. Future studies are warranted to elucidate the molecular mechanisms underlying pathological processes mediated by mutual key proteins.
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